OBJECTIVE: Gallbladder cancer is characterized by high morbidity and mortality. An appropriate human xenograft animal model could serve as a research tool to investigate new therapeutic strategies. SUMMARY BACKGROUND DATA: To date, the few reports describing a xenograft animal model showed significant limitations. We improved a murine orthotopic human xenotransplantation model by implanting human gallbladder carcinoma cells directly into the lumen of the gallbladder. METHODS: Mz-ChA-1 cells were orthotopically injected into the gallbladder of Severe Combined Immune Deficiency (SCID) beige mice inducing the growth of solid tumors. The natural course of the disease, tumor growth, and metastases were analyzed. The cytotoxic drug gemcitabine was tested in vitro and in vitro. RESULTS: All animals revealed solid tumors in the inoculated area with liver infiltration. The median tumor volume in the untreated group was significantly higher than in the gemcitabine-treated group. Immunohistochemical staining revealed expression of human cytokeratin 7 and cytokeratin 8. To analyze tumor cell proliferation, the tumors were stained for the antigen Ki-67, and labeling indices were calculated for both groups. Animals receiving gemcitabine treatment showed significantly lower mean labeling indices. In vitro investigation revealed a significant reduction of DNA synthesis. DNA fragmentation, as a measure of apoptosis, was elevated by roughly 20% within 24 h of treatment. With this, we successfully established an orthotopic xenotransplant animal model and investigated the in vitro and in vivo effects of gemcitabine in human xenografted Mz-ChA-1 gallbladder adenocarcinoma. CONCLUSION: This model resembles the clinical situation as closely as possible and offers a relevant option for the preclinical testing of new therapeutic strategies.
OBJECTIVE: Gallbladder cancer is characterized by high morbidity and mortality. An appropriate human xenograft animal model could serve as a research tool to investigate new therapeutic strategies. SUMMARY BACKGROUND DATA: To date, the few reports describing a xenograft animal model showed significant limitations. We improved a murine orthotopic human xenotransplantation model by implanting humangallbladder carcinoma cells directly into the lumen of the gallbladder. METHODS: Mz-ChA-1 cells were orthotopically injected into the gallbladder of Severe Combined Immune Deficiency (SCID) beige mice inducing the growth of solid tumors. The natural course of the disease, tumor growth, and metastases were analyzed. The cytotoxic drug gemcitabine was tested in vitro and in vitro. RESULTS: All animals revealed solid tumors in the inoculated area with liver infiltration. The median tumor volume in the untreated group was significantly higher than in the gemcitabine-treated group. Immunohistochemical staining revealed expression of humancytokeratin 7 and cytokeratin 8. To analyze tumor cell proliferation, the tumors were stained for the antigen Ki-67, and labeling indices were calculated for both groups. Animals receiving gemcitabine treatment showed significantly lower mean labeling indices. In vitro investigation revealed a significant reduction of DNA synthesis. DNA fragmentation, as a measure of apoptosis, was elevated by roughly 20% within 24 h of treatment. With this, we successfully established an orthotopic xenotransplant animal model and investigated the in vitro and in vivo effects of gemcitabine in human xenografted Mz-ChA-1 gallbladder adenocarcinoma. CONCLUSION: This model resembles the clinical situation as closely as possible and offers a relevant option for the preclinical testing of new therapeutic strategies.
Authors: V Gebbia; F Giuliani; E Maiello; G Colucci; F Verderame; N Borsellino; G Mauceri; M Caruso; M L Tirrito; M Valdesi Journal: J Clin Oncol Date: 2001-10-15 Impact factor: 44.544
Authors: S Tesana; Y Takahashi; P Sithithaworn; K Ando; T Sakakura; W Yutanawiboonchai; C Pairojkul; W Ruangjirachuporn Journal: Parasitol Int Date: 2000-09 Impact factor: 2.230
Authors: Steven R Alberts; Hani Al-Khatib; Michelle R Mahoney; Lawerence Burgart; Peter J Cera; Patrick J Flynn; Tom R Finch; Ralph Levitt; Harold E Windschitl; James A Knost; Loren K Tschetter Journal: Cancer Date: 2005-01-01 Impact factor: 6.860
Authors: A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde Journal: J Hepatol Date: 1985 Impact factor: 25.083
Authors: Y Shimizu; A J Demetris; S M Gollin; P D Storto; H M Bedford; S Altarac; S Iwatsuki; R B Herberman; T L Whiteside Journal: Int J Cancer Date: 1992-09-09 Impact factor: 7.396
Authors: T Tengchaisri; N Prempracha; W Thamavit; S Boonpucknavig; S Sriurairatana; S Sirisinha Journal: Southeast Asian J Trop Med Public Health Date: 1995-06 Impact factor: 0.267
Authors: Daniel J Spade; Elizabeth V McDonnell; Nicholas E Heger; Jennifer A Sanders; Camelia M Saffarini; Philip A Gruppuso; Monique E De Paepe; Kim Boekelheide Journal: Birth Defects Res B Dev Reprod Toxicol Date: 2014-12-04
Authors: Stephan Philipp; Justyna Sosna; Johannes Plenge; Holger Kalthoff; Dieter Adam Journal: Cell Commun Signal Date: 2015-04-29 Impact factor: 5.712
Authors: Susann Voigt; Stephan Philipp; Parvin Davarnia; Supandi Winoto-Morbach; Christian Röder; Christoph Arenz; Anna Trauzold; Dieter Kabelitz; Stefan Schütze; Holger Kalthoff; Dieter Adam Journal: BMC Cancer Date: 2014-02-07 Impact factor: 4.430